Urology Medical News about erlotinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro
The Prostate, 06/30/09

Festuccia C et al. - In a study to determine why EGFR inhibitors been so ineffective in human prostate cancer (PCa), the results seem to suggest that a low EGFR/Her2 ratio and PTEN absence are the main factors responsible of erlotinib inefficacy. The inhibition of EGFR could have important antitumor effects in hormone-naive rather than in hormonally treated pts.

Methods

The effectiveness of erlotinib was assessed in a wide range of PCa cells (wild type or engineered to overexpress peculiar proteins including androgen receptor and PTEN).

Results

The effectiveness of erlotinib was inversely correlated to the EGFR/Her2 ratio rather than EGFR/p-EGFR or Her2/p-Her2 levels.
Chronic treatment with bicalutamide induced overexpression of Her2 and reduction of EGFR/Her2 ratio and this was associated with increased Akt and Erk activity.
In these treatment conditions, a reduced efficacy of erlotinib was observed.
At the same time, an increased efficacy vs erlotinib was documented in cancer cells chronically exposed to DHT.
In these culture conditions, low levels of Her2 and increased EGFR/Her2 ratio were evidenced.

<< Previous
Modeling the effects of obesity and weight gain on PSA velocity

Next >>
The FOXF2 pathway in the human prostate stroma